Results 21 to 30 of about 101,617 (297)
DPP-4 Inhibitors—Renoprotection in Diabetic Nephropathy? [PDF]
Diabetes, 2014 There is no doubt that rates of chronic kidney disease are escalating and that this rise is the main contributor to the increasing prevalence of diabetic nephropathy. It is also clear that the increase in kidney failure continues despite tight blood glucose and blood pressure control, as well as renin-angiotensin system blockade.
Usha, Panchapakesan, Carol A, Pollock
openaire +2 more sources
International Journal of Endocrinology, 2014 Dipeptidyl-4 (DPP-4) inhibitors are oral antidiabetic agents recently introduced to Malaysia. Thus, limited data is available on their utilization patterns and factors associated with their use.
Hasniza Zaman Huri +2 more
doaj +1 more source
Cardiovascular effects of the DPP-4 inhibitors
Diabetes and Vascular Disease Research, 2012 Type 2 Diabetes continues to rise in prevalence throughout the globe, and cardiovascular diseases remain the most common cause of morbidity and mortality among patients. Dipeptidyl-peptidase-4 (DPP-4) inhibitors are a newer class of oral anti-hyperglycemic agents whose effect is mediated through the incretin hormones, GLP-1 and GIP.
Tessey, Jose, Silvio E, Inzucchi
openaire +2 more sources
Relook at DPP-4 inhibitors in the era of SGLT-2 inhibitors
World Journal of Diabetes, 2022 SGLT-2 inhibitors (SGLT-2Is) have significantly improved cardio-renal outcomes and are preferred agents in people with cardiovascular diseases, heart failure, and diabetic kidney disease. Similarly, GLP-1 receptor agonists (GLP-1RAs) have significantly improved atherosclerotic cardiovascular outcomes. To this end, DPP-4 inhibitors (DPP-4Is) are cardiac-
Singh, Awadhesh Kumar, Singh, Ritu
openaire +2 more sources
, 2016 Dipeptidyl peptidase (DPP)-4 inhibitors inhibit the activity of the enzyme responsible for the initial rapid degradation of the incretin hormones, thereby enhancing their antihyperglycemic ...
Deacon, Carolyn F., Carolyn F Deacon
core +1 more source
Additional file 1 of The effect of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors on cardiorenal outcomes: a network meta-analysis of 23 CVOTs [PDF]
, 2022 Additional file 1: Figure S1. Process of studies’ selection. Table S1. Summary of risk of bias assessment. Figure S2. Cochrane risk of bias (graph) for the 23 trials. Figure S3.
Dario Giugliano (10218354) +6 more
core +1 more source
BMC Endocrine Disorders, 2019 Background Dipeptidyl peptidase-4 (DPP-4) inhibitors could effectively reduce HbA1C and postprandial hyperglycemia and could incur only minimal danger of hypoglycemia.
Fu-Shun Yen +6 more
doaj +1 more source
, 2012 International audienceAlthough being a primary objective in the management of type 2 diabetes, optimal glycaemic control is difficult to achieve and usually not maintained over time.
Staels, Bart +5 more
core +2 more sources
Journal of Pharmacological Sciences, 2017 Dipeptidyl peptidase-4 (DPP-4) inhibitors are a new class of oral hypoglycemic agents for patients with type 2 diabetes mellitus and have potential antiatherosclerotic properties.
Akari Nagamine +8 more
doaj +1 more source
Predictive Factors for Efficacy of Dipeptidyl Peptidase-4 Inhibitors in Patients with Type 2 Diabetes Mellitus [PDF]
Diabetes & Metabolism Journal, 2015 BackgroundPredictive factors for the efficacy of dipeptidyl peptidase-4 (DPP-4) inhibitors for lowering glycosylated hemoglobin (HbA1c) remain unclear in patients with type 2 diabetes mellitus.
Shusuke Yagi +15 more
doaj +1 more source